Topiramate
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Topiramate: From Epilepsy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Topiramate is an anticonvulsant originally used for epilepsy (generalized tonic-clonic seizures, partial epilepsy and Lennox-Gastaut syndrome). The TxGNN model’s top-ranked prediction is trigeminal nerve neoplasm, but there are no clinical trials and no publications supporting it; this is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (generalized tonic-clonic seizures, partial epilepsy, Lennox-Gastaut syndrome) |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 0.9970 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
The original indications come from the TxGNN knowledge graph’s record of known uses, because the Indian licence records contain no indication text.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Topiramate is a broad-spectrum antiseizure drug, and its efficacy in epilepsy is established. Literature retrieved for other predictions describes its actions as sodium channel blockade, GABA-A enhancement, AMPA/kainate antagonism and weak carbonic anhydrase inhibition.
For the top-ranked prediction, trigeminal nerve neoplasm, none of these actions has an established link to tumour biology. Any benefit would at most be symptomatic, for example control of related neuropathic pain, and the data compiled here do not support even that. The very high score (0.9970) should therefore be treated as a model output, not as evidence of efficacy.
The other predictions are more plausible mechanistically because they are seizure disorders:
| Rank | Predicted Indication | Score | Evidence Level | Assessment | |—|—|—|—|—|
Clinical Trial Evidence
Currently no related clinical trials registered, for the top-ranked prediction or for any of the other predictions listed above.
Literature Evidence
For the top-ranked prediction (trigeminal nerve neoplasm), currently no related literature available.
The most relevant publications retrieved for the other predictions are shown below. They support topiramate’s general antiseizure activity, not the specific predicted conditions.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24570033 | 2014 | Cochrane systematic review | Cochrane Database Syst Rev | Summarizes evidence for topiramate as add-on treatment in drug-resistant partial epilepsy |
| 31642054 | 2019 | Cochrane review | Cochrane Database Syst Rev | Updated review of topiramate add-on therapy for drug-resistant focal epilepsy |
| 18646072 | 2008 | Cochrane systematic review | Cochrane Database Syst Rev | Add-on topiramate in drug-resistant partial epilepsy |
| 39854828 | 2025 | Review/consensus | Epilepsy Behav | Topiramate is among the FDA-approved antiseizure medications for Lennox-Gastaut syndrome |
| 10666508 | 2000 | Preclinical (animal) | Eur J Pharmacol | Topiramate antagonized audiogenic seizures in DBA/2 mice and potentiated other anticonvulsants |
| 12581224 | 2003 | Preclinical (animal) | Epilepsia | Antiepileptic effects in genetic absence and audiogenic rat models |
| 35421622 | 2022 | Review | Seizure | Molecular mechanisms of topiramate and its clinical value in epilepsy |
| 30687937 | 2019 | Cochrane review | Cochrane Database Syst Rev | Efficacy and tolerability of topiramate in juvenile myoclonic epilepsy |
| 19173373 | 2009 | Review | CNS Drugs | Antiepileptic drugs, topiramate in particular, may help in some eating disorders |
| 40742426 | 2025 | Review | Epilepsia | Topiramate for neonatal seizures and beyond |
India Market Information
Twenty valid single-ingredient registrations are on record. The main ones are listed below; the licence records contain no approved indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 222437 | Topomed 25mg Tablet (Emocare) | Strip of 10 tablets | Not stated in the records |
| 222550 | Torpiza 50mg Tablet (Emcure Pharmaceuticals Ltd) | Strip of 10 tablets | Not stated in the records |
| 215112 | Topamac 50mg Tablet (Janssen Pharmaceuticals) | Strip of 10 tablets | Not stated in the records |
| 222063 | Topamate 100mg Tablet (Cipla Ltd) | Strip of 10 tablets | Not stated in the records |
| 220296 | Topiram 50mg Tablet (Zydus Cadila) | Strip of 10 tablets | Not stated in the records |
Safety Considerations
Contraindication-related conditions (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, kidney disease, pyoureter, liver disease, gallbladder disease, diarrheal disease, ocular hypertension, nephrolithiasis (including SLC26A1-related susceptibility), acute urate nephropathy, acidosis disorder, metabolic acidosis, amnestic disorder and retrograde amnesia.
Drug Interactions: 187 interactions are recorded. The main ones are:
- Major: metformin; anticholinergic/antimuscarinic agents (hyoscyamine, atropine, scopolamine, glycopyrronium, clidinium, dicyclomine, mepenzolate, methscopolamine, propantheline, trospium)
- Moderate: pioglitazone, glyburide, morphine, dronabinol, nabilone, phentermine, metoclopramide, phenylbutyric acid, glycerol phenylbutyrate
Literature retrieved for other predictions also points to adverse-event concerns, including pregnancy complications, psychiatric effects (psychosis, mania) and adverse reactions in children. Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, trigeminal nerve neoplasm, rests solely on a model score (Evidence Level L5), with no trials, no literature and no plausible mechanistic link to tumour biology. The seizure-related predictions are more credible but are indirect extensions of the existing epilepsy indication. Audiogenic seizures, which have animal-model support, is the only one flagged as a research question.
To proceed, the following is needed:
- Mechanism of action data (MOA) to allow a proper mechanistic analysis
- Package insert warnings and contraindications from the Indian regulator, which are currently missing and block safety screening
- Disease-specific clinical evidence (case series or trials) for any candidate indication, especially the reflex epilepsies
- For trigeminal nerve neoplasm, preclinical or clinical evidence of a tumour-related or symptomatic benefit before any further consideration
- Confirmation that the predicted seizure conditions add value beyond the already-approved epilepsy indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.